
The FDA Is Moving Past Animal Testing. Here’s How Ncardia Helps Make It Happen

Press release: Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study

Ncardia Acquires STAR-CRISPR Technology for Advanced Gene Editing of iPSCs

Unveiling Ncardia's Path to Innovation and Growth

The Urgent Need for Reliable Cell Models in ALS Research

Ncardia's Remarkable Journey in 2023